Volume 28, Number 1—January 2022
Synopsis
Outbreak of Mucormycosis in Coronavirus Disease Patients, Pune, India
Samir Joshi, Rahul Telang, Muralidhar Tambe, Rajesh Havaldar
, Manasi Sane, Afshan Shaikh, Cherry Roy, Kireet Yathati, Sanjaykumar Sonawale, Rupalee Borkar, Rahul Magar, Harshal Bhitkar, Satish Shitole, Leena Nakate, Jyoti Kudrimoti, and Vidya Mave
, Manasi Sane, Afshan Shaikh, Cherry Roy, Kireet Yathati, Sanjaykumar Sonawale, Rupalee Borkar, Rahul Magar, Harshal Bhitkar, Satish Shitole, Leena Nakate, Jyoti Kudrimoti, and Vidya Mave
Table 1
Clinical characteristics of patients experiencing intensive rhino-sino-orbital and cerebral mucormycosis after undergoing treatment for COVID-19, India
| Characteristic | No. case-patients, n = 178 |
|---|---|
| Age | |
| Age, y, median (range) | 51 (42–60) |
| Age group | |
| <18 | 1 (1) |
| 18–45 | 52 (29) |
| 45–65 | 103 (58) |
| >65 |
22 (12) |
| Sex | |
| M | 125 (70) |
| F |
53 (30) |
| Underlying illness | |
| Diabetes mellitus | |
| Previously diagnosed | 88 (49) |
| Newly diagnosed | 44 (25) |
| Hypertension | 48 (27) |
| Chronic kidney disease | 5 (3) |
| Cardiomyopathy | 4 (2) |
| Asthma | 2 (1) |
| HIV |
1 (1) |
| COVID-19 characteristics† | |
| Moderate COVID-19 | 122 (77) |
| Mild COVID-19 | 29 (18) |
| Severe COVID-19 | 8 (5) |
| Hospitalization, d, median (IQR) | 10 (8–15) |
| Required oxygenation | 103 (69) |
| Required ventilator support | 5 (4) |
| Received intravenous steroids | 82 (67) |
| Received oral steroids | 12 (17) |
| Received antimicrobial drugs |
95 (98) |
| Symptoms of mucormycosis | |
| Facial pain | 132 (74) |
| Headache | 96 (54) |
| Nasal congestion | 79 (44) |
| Nasal discharge | 57 (32) |
| Vision impairment | 66 (37) |
| Time from COVID-19 diagnosis to mucormycosis symptom onset, d (IQR) |
28 (15–45) |
| Vital signs | |
| Temperature, °F, median (IQR) | 98 (98–98.6) |
| Heart rate >100 beats/min | 4 (2) |
| Heart rate, beats/min, median (IQR) | 88 (86–90) |
| Respiratory rate >20 breaths/min | 29 (16) |
| Respiratory rate, breaths/min, median (IQR) | 16 (12–18) |
| Median BP, systolic, mm Hg | 123 (120–128) |
| Median BP, diastolic, mm Hg | 80 (80–86) |
*Values are no. (%) patients except as indicated. BP, blood pressure; COVID-19, coronavirus disease; IQR, interquartile range. †These characteristics represent diagnosis and treatment provided for COVID-19 prior to mucormycosis events.
Page created: September 24, 2021
Page updated: December 20, 2021
Page reviewed: December 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.